
### Plasma Product Biotechnology meeting 2017


### Survey responses

(90 responses received)






#### Please indicate your affiliation






#### How did you find out about the conference?






### What attracted you to the conference?





### Please indicate your opinion about the following





# What other areas relevant to plasma biotherapeutics would you like to see addressed?

More on recombinant plasma proteins

Pitfalls for successful submissions

Presentations from Asia / Developing countries

Quality control of plasma products

More science

Focus on cost challenges, how does the industry react

Continuous processing

Equipment and technology related topics


**GMP** topics

More clinical studies

IVIG issues, such as thrombogenic factors and atypical antibodies



#### Which sessions were of most interest?





### What was the most significant development you were made aware of during PPB17?

Fc multimers as IVIG mimetics

Latin hypercube sampling

Use of SOMAscan

Increase in fractionation capacity

Inline conditioning/buffer management

Plasma availability discussions

Network, information from other companies

Nebulize IgG for treatment


FVII by LFB

New development IAIP for stroke

Patient perspectives




### What is your overall rating of PPB17






#### Would you recommend PPB to a colleague? (10=absolutely, 1=never)






## Please rate the information through PPB17 website / Linked In group






#### Please rate the following





### Do you think another PPB conference should be held in 2019?





### What would your preferred location for the next PPB conference be?

